Comparative Pharmacology
Head-to-head clinical analysis: ALPHADERM versus FLUOCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHADERM versus FLUOCINOLONE ACETONIDE.
ALPHADERM vs FLUOCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Fluocinolone acetonide is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cytokines (e.g., IL-1, IL-2, TNF-α). It also causes vasoconstriction and decreases cellular migration and immune response.
Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply thin film to affected area 2-4 times daily. Otic: 0.01% solution, 5 drops into ear canal twice daily. Intralesional: 3.3 mg/mL, 0.5-1 mL per injection every 1-2 weeks.
None Documented
None Documented
Clinical Note
moderateFluocinolone acetonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Gatifloxacin."
Clinical Note
moderateFluocinolone acetonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Rosoxacin."
Clinical Note
moderateFluocinolone acetonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life is approximately 1.3-1.5 hours following topical application; after systemic absorption (oral or injection), half-life is 1.5-2.0 hours, necessitating multiple daily dosing for sustained effect.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; less than 10% metabolized hepatically.
Primarily hepatic metabolism with renal excretion of metabolites (approximately 80% renal, 20% biliary/fecal). Less than 1% excreted unchanged in urine.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
Fluocinolone acetonide + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Trovafloxacin."